Research Topics
| Jonathan W SimonsSummaryAffiliation: Emory University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancerJonathan W Simons
Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Urol Oncol 24:419-24. 2006..Multi-institutional phase III investigation is currently underway to evaluate the impact of allogeneic prostate GVAX cellular immunotherapy on time to progression and overall survival in hormone refractory prostate cancer...- Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cellsCeshi Chen
Winship Cancer Institute and Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
J Biol Chem 280:41553-61. 2005..These findings not only established WWP1 as an E3 ubiquitin ligase for KLF5, they also further implicated the KLF5 pathway in human carcinogenesis... - Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancerXiaodong Sun
Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Nat Genet 37:407-12. 2005..Furthermore, ATBF1 inhibited cell proliferation. Hence, loss of ATBF1 is one mechanism that defines the absence of growth control in prostate cancer... 
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cellsTISHEEKA R GRAHAM
Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Cancer Res 68:2479-88. 2008..These results identify ZEB1 as a key transcriptional regulator of EMT in prostate cancer and suggest that the aberrant expression of ZEB1 in prostate cancer cells occurs in part in response to IGF-I stimulation...- KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell lineCeshi Chen
Winship Cancer Institute and Department of Oncology and Hematology, Emory University School of Medicine, Atlanta, GA, USA
Int J Cancer 118:1346-55. 2006..These findings suggest that the KLF5 transcription factor plays an oncogenic role in the TSU-Pr1 bladder cancer cell line through the regulation of a subset of genes... - Quantum dots: emerging applications in urologic oncologyChunmeng Shi
Molecular Urology and Therapeutics Program, Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA
Urol Oncol 26:86-92. 2008..In this article, we describe the development of multifunctional QDs and their potential applications in oncology, with a particular emphasis on the diagnosis, prognosis, and treatment of urologic cancers... - Nanotechnology for targeted cancer therapyMay D Wang
Georgia Institute of Technology, Department of Biomedical Engineering, and Emory University, Atlanta, GA 30332, USA
Expert Rev Anticancer Ther 7:833-7. 2007.... - Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor modelSeung-Hee Kang
Department of Hematology/Oncology, Emory University, School of Medicine, Atlanta, Georgia 30322, USA
Cancer Res 66:11991-7. 2006.... - Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancerJonathan W Simons
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Clin Cancer Res 12:3394-401. 2006.... - Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cellsNicola J Mabjeesh
Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Clin Cancer Res 9:2416-25. 2003..Therapeutic actions of antiandrogens in PCA include inhibition of HIF-1 function... - Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesisHua Zhong
Department of Hematology and Oncology, Winship Cancer Institute, Emory University, 1365 B Clifton Road, N E Room B4328, Atlanta, GA 30322, USA
Cancer Detect Prev 28:88-93. 2004.... - Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cellsCeshi Chen
Department of Oncology and Hematology, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, Atlanta, GA, USA
Oncogene 24:3319-27. 2005..These results suggest that KLF5 protein is degraded at least in part through ubiquitination-proteasome pathway, which may have become hyperactive for KLF5 in cancer cells... - Novel therapeutic strategies for androgen-independent prostate cancer: an updateVasily J Assikis
Winship Cancer Institute Prostate Cancer Translational Research Program, Emory University, Atlanta, GA 30322, USA
Semin Oncol 31:26-32. 2004..Such new therapeutic modalities, along with recent data on immunotherapy and bone targeting strategies, will be reviewed here... - Nanotechnology applications in cancerShuming Nie
Department of Biomedical Engineering and the Winship Cancer Institute, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA
Annu Rev Biomed Eng 9:257-88. 2007..These developments raise exciting opportunities for personalized oncology in which genetic and protein biomarkers are used to diagnose and treat cancer based on the molecular profiles of individual patients... - 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIFNicola J Mabjeesh
Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
Cancer Cell 3:363-75. 2003..These data establish 2ME2 as a small molecule inhibitor of HIF-1 and provide a mechanistic link between the disruption of the MT cytoskeleton and inhibition of angiogenesis... - Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistryYun Xing
Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 101 Woodruff Circle Suite 1001, Atlanta, Georgia 30322, USA
Nat Protoc 2:1152-65. 2007..In general, QD bioconjugation is completed within 1 day, and multiplexed molecular profiling takes 1-3 days depending on the number of biomarkers and QD probes used... - Exploitation of the HIF axis for cancer therapyDaniel Escuin
Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
Cancer Biol Ther 3:608-11. 2004..We will overview inhibitors of HIF-1alpha and will discuss their potential use for cancer therapy... - Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cellsNicola J Mabjeesh
Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Cancer Res 62:2478-82. 2002..Thus, benzoquinone ansamycin drugs and their derivatives, such as 17-allyl-aminogeldanamycin, are excellent candidates as small molecule drug inhibitors of HIF-1 overexpression in cancer cells... - Dibenzoylmethane, a natural dietary compound, induces HIF-1 alpha and increases expression of VEGFNicola J Mabjeesh
Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365-B Clifton Road, Atlanta, GA 30322, USA
Biochem Biophys Res Commun 303:279-86. 2003..Mechanistically, HIF-1 alpha was stabilized by DBM at a step prior to ubiquitination. The effect of DBM on HIF-1 and its low toxicity profile might be therapeutically beneficial in ischemic diseases... - HIF at the crossroads between ischemia and carcinogenesisStefan A M Paul
Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany
J Cell Physiol 200:20-30. 2004..The consequences of the switch of HIF activation in these two disease states and the signaling pathway overlap that atherosclerosis and cancer angiogenesis share are discussed... - Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano
Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
Cancer 113:975-84. 2008..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)... - MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesisSharon Amir
Prostate Cancer Research Laboratory, Department of Urology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 64239 Tel Aviv, Israel
Cancer Res 66:856-66. 2006..Xenograft-derived human tumors from these cells were larger and more vascular. These findings link a function of a septin protein with angiogenesis through activation of the HIF pathway... - Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancerEric J Small
University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California 94115, USA
Clin Cancer Res 13:3883-91. 2007..The immunotherapy, based on the GVAX platform, is a combination of two prostate carcinoma cell lines modified with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene...